Hikma launches Methotrexate for Inection in USA, which sold for $13 million last year

Hikma Pharmaceuticals’s US subsidiary West-Ward Pharmaceuticals has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection, which had US sales for Injection, USP, 1g and Methotrexate Injection, USP, 50mg/2mL, about $13 million in the last 12 months, according to IQVIA.

Riad Mechlaoui, Chief Executive Officer Injectables, said: “Our continued progress in executing our injectables pipeline demonstrates our strong R&D, regulatory and manufacturing capabilities.”

Methotrexate for Injection, USP and Methotrexate Injection, USP are indicated for use in the the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole, acute lymphocytic leukemia, treatment of breast cancer, advanced mycosis fungoides, lung cancer.

Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas, and in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.